The prevalence of anti-rubella antibodies in women of childbearing age in Poland.

Congenital rubella is a clinically serious problem, which is due to maternal infection with rubella virus during the first trimester of pregnancy. It may result in spontaneous abortion or in fetal infection leading to fetal birth defect. Maternal anti-rubella antibodies have a protective effect and they may prevent congenital rubella.

[Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population].

The data according number of cases and morbidity rates of measles, mumps and rubella as well as antibody prevalence against diseases above mentioned in Polish population were shown. The impact of mass vaccination on decreasing of measles incidence and number of reported rubella congenital syndrome was observed. The possibility of elimination these diseases in the near future was discussed.

[Immunity of children aged 6-8 against pertussis, tetanus and diphtheria].

Vaccination against pertussis has been performed since 1960. Whole cell pertussis vaccine produced by Plant of Sera and Vaccines Biomed S.A.

[Examination of protein MPB 70 properties in BCG substrains used for the production of Polish antituberculosis vaccines].

The aim of the study was examination of MPB70 protein production by different BCG substrains and testing this protein as reagent in allergenic skin test on BCG vaccinated guinea pigs. Three BCG substrains: Danish 1331 (D), Japanese 172 (J) and Polish BCG Moreau (P) were used for the study. The protein MPB70 received from dr Nagai from Osaka University was used as reference preparation.

[Controlled release antigen from the injection site--new model for a single-shot vaccination?].

Continuously increasing number of available vaccines and a wide use of mass vaccination campaigns lead to the development of simpler methods of vaccine delivery. There is the WHO-sponsored project, including several scientific groups, which aims to reduce the number of repeated administrations of vaccines required for long-term protection and to obviate the need for booster immunization. Such a task may be achieved by the use of controlled-release parenteral systems.